Related by context. All words. (Click for frequent words.) 80 stage IIIB 77 recurrent NSCLC 76 advanced unresectable 75 resectable 74 metastatic NSCLC 74 IV NSCLC 73 metastatic GIST 73 metastatic renal cell carcinoma 73 metastatic RCC 72 unresectable locally advanced 71 metastatic malignant 71 fallopian tube carcinoma 70 non squamous NSCLC 70 metastatic pancreatic cancer 70 mRCC 70 stage IIIA 69 stage IIIb IV 69 relapsed refractory multiple myeloma 69 metastatic gastric 69 histologically confirmed 69 hepatic metastases 68 metastatic HER2 negative 68 recurrent metastatic 68 chemoradiotherapy 68 metastatic bladder 68 refractory multiple myeloma 68 malignant pleural mesothelioma 68 HER2 positive metastatic breast 68 neoadjuvant therapy 68 gemcitabine chemotherapy 68 relapsed SCLC 67 neoadjuvant chemotherapy 67 dacarbazine 67 locoregional 67 carboplatin paclitaxel 67 advanced hepatocellular carcinoma 67 refractory AML 67 curative resection 67 vinorelbine 67 unresectable stage 67 situ CIS 67 NSCLC 67 liver metastases 67 recurrent glioblastoma multiforme 67 metastatic pancreatic 67 tumors GIST 67 platinum refractory 67 stage IIIB IV 67 refractory NSCLC 67 metastatic malignant melanoma 66 non squamous 66 cell lymphoma CTCL 66 FOLFIRI 66 FOLFOX4 66 soft tissue sarcomas 66 HER2 negative 66 metastatic carcinoma 66 dacarbazine DTIC 66 sorafenib Nexavar 66 gastrointestinal stromal tumor GIST 66 interferon alfa 2a 66 FOLFOX 66 heavily pretreated patients 66 docetaxel Taxotere ® 66 refractory chronic lymphocytic 66 vandetanib 66 lymphoma CTCL 66 anthracycline taxane 66 leukemia AML 66 minimally symptomatic 66 HBeAg negative 66 medically inoperable 66 anthracycline containing 66 TACE 66 temsirolimus 65 chlorambucil 65 dasatinib Sprycel ® 65 medullary thyroid cancer 65 IV melanoma 65 IV metastatic melanoma 65 nonmetastatic 65 remission induction 65 intravesical therapy 65 cytotoxic chemotherapy 65 gastrointestinal stromal tumors 65 mCRC patients 65 metastatic colorectal 65 chemoradiation therapy 65 sunitinib Sutent 65 leukemia CLL 65 heavily pretreated 65 hepatocellular carcinoma HCC 65 IIIB NSCLC 65 metastatic 65 paclitaxel carboplatin 65 colorectal liver metastases 65 hormone refractory prostate cancer 65 cutaneous T cell 65 Amrubicin 65 squamous histology 65 advanced NSCLC 65 non metastatic osteosarcoma 65 metastatic SCCHN 65 pancreatic adenocarcinoma 65 small lymphocytic lymphoma 65 KRAS wild 65 B CLL 65 Peginterferon alfa 2b 65 fludarabine 65 distant metastasis 65 biliary tract cancer 65 metastatic disease 65 unresectable Stage III 65 chemoradiation 65 plus gemcitabine 65 TORISEL 65 completely resected 64 gemcitabine carboplatin 64 HES CEL 64 adjuvant therapy 64 metastatic CRC 64 postoperative chemotherapy 64 adjuvant radiation 64 Surgical resection 64 gemcitabine 64 metastatic castration resistant 64 adjuvant radiotherapy 64 Doxil ® 64 renal cell carcinoma 64 myelodysplastic syndrome MDS 64 squamous 64 metastatic medullary thyroid 64 bevacizumab Avastin 64 Fludara 64 advanced metastatic renal 64 Hepatocellular Carcinoma HCC 64 lung metastases 64 resected 64 metastatic colorectal cancer 64 eribulin mesylate 64 FOLFOX6 64 gastrointestinal stromal tumors GIST 64 5-FU/LV 64 concurrent chemoradiation 64 BCG refractory 64 metastatic squamous cell carcinoma 64 hypercalcemia 64 superficial bladder cancer 64 radical nephrectomy 64 Tarceva TM 64 unresectable tumors 64 pancreatic NET 64 erlotinib Tarceva ® 64 Bezielle 64 irinotecan containing 64 unresectable recurrent 64 metastatic melanoma 63 primary peritoneal 63 CLL SLL 63 distant metastases 63 allogeneic stem cell 63 hepatocellular carcinomas 63 preoperative chemotherapy 63 taxane refractory 63 cetuximab Erbitux ® 63 cystectomy 63 XELOX 63 fluorouracil 63 Advanced Renal Cell 63 metastatic castrate resistant 63 prostate cancer CRPC 63 infusional 5-FU/LV 63 CTEPH 63 follicular lymphoma FL 63 CHOP chemotherapy 63 bendamustine 63 Pemetrexed 63 tumor recurrence 63 sorafenib 63 neoadjuvant 63 estramustine 63 differentiated thyroid 63 DOXIL 63 sunitinib 63 chronic ITP patients 63 arthritis PsA 63 Li Fraumeni Syndrome 63 refractory Hodgkin lymphoma 63 cetuximab Erbitux R 63 doublet chemotherapy 63 percutaneous ablation 63 NYHA Class II 63 VELCADE melphalan 63 metastatic HER2 positive 63 chemotherapy cisplatin 63 achieved ACR# 63 pegylated liposomal doxorubicin 63 Allovectin 7 ® 63 Castration Resistant Prostate Cancer 63 Navelbine ® 63 taxane chemotherapy 63 Trastuzumab 63 pemetrexed 63 ACTEMRA TM 63 hypereosinophilic syndrome 63 revascularization procedures 63 HER2 positive 63 epithelial ovarian 63 recurrent glioblastoma 63 pT2 63 Relapsed 63 non resectable 63 pheochromocytoma 63 trabectedin 63 Adjuvant chemotherapy 63 gastrointestinal stromal tumor 63 nonsmall cell lung cancer 63 cisplatin gemcitabine 63 cancer mCRC 63 epirubicin 63 imatinib resistant 62 interferon alfa 2b 62 cytoreductive surgery 62 evaluating REVLIMID 62 bevacizumab Avastin ® 62 Fludarabine 62 receptor tyrosine kinase inhibitor 62 GISTs 62 refractory acute myeloid 62 relapsed refractory 62 epithelial tumors 62 standard chemotherapy regimens 62 Pegasys ® 62 5 fluorouracil leucovorin 62 nilotinib Tasigna ® 62 underwent resection 62 thromboembolic events 62 adriamycin 62 Paraplatin ® 62 azacitidine 62 adjuvant chemotherapy 62 biologic therapy 62 solid tumors 62 Torisel 62 soft tissue sarcoma 62 saline placebo 62 plus dexamethasone 62 castration resistant prostate cancer 62 renal tumors 62 pancreatic carcinoma 62 Gemcitabine 62 pneumonectomy 62 metastatic neuroendocrine tumors 62 hepatocellular cancer 62 Hurthle cell 62 localized renal 62 prostate cancer HRPC 62 docetaxel Taxotere R 62 lymph node metastases 62 non splenectomized 62 5FU 62 TTF Therapy 62 lymphadenectomy 62 Irinotecan 62 metastatic liver 62 metastatic HRPC 62 multiple myeloma MM 62 axitinib 62 thymoma 62 FOLPI 62 Soft Tissue Sarcoma 62 Platinol 62 Lenalidomide 62 chronic plaque psoriasis 62 CIMZIA ™ 62 fluoropyrimidine 62 cisplatin chemotherapy 62 idarubicin 62 systemic ALCL 62 cytoreduction 62 SCCHN 62 mCRC 62 CYT# potent vascular disrupting 62 Tarceva erlotinib 62 gastroesophageal junction 62 Kit CD# positive 62 4mg/kg 62 Stage IIIb 62 Taxotere ® 62 basal cell carcinoma BCC 62 Cutaneous T 62 fallopian tube cancers 62 rheumatoid arthritis RA psoriatic 62 cervical carcinoma 62 lenalidomide Revlimid R 62 pT3 62 plus dacarbazine 62 metastatic lung cancer 62 grade cervical intraepithelial 62 cytologically confirmed 62 Metastatic breast cancer 62 docetaxel Taxotere 62 resistant hormone refractory 62 papillary renal cell carcinoma 62 refractory colorectal cancer 62 pegylated interferon alfa 2a 62 Patients Treated With 62 non splenectomised 62 EGFR expressing 62 ribavirin therapy 62 ribavirin RBV 62 glufosfamide 62 brain metastases 62 Folfox 62 recurrent prostate cancer 62 TELCYTA 62 relapsed MM 62 taxane therapy 62 metastatic prostate cancer 62 stage IIIb 62 KRAS mutations occur 62 Capecitabine 62 ovarian carcinoma 62 metastatic hormone refractory 62 cutaneous T 61 histologies 61 myelodysplastic myeloproliferative diseases 61 chronic eosinophilic leukemia 61 metastatic relapsed 61 liposomal doxorubicin 61 unresectable hepatocellular carcinoma HCC 61 oral Hycamtin 61 refractory cutaneous T 61 irinotecan chemotherapy 61 placebo dexamethasone 61 YONDELIS 61 chronic HCV 61 immunomodulatory therapy 61 melphalan prednisone 61 REMICADE ® 61 essential thrombocythemia ET 61 docetaxel chemotherapy 61 vWD 61 EGFR expressing metastatic colorectal 61 Genasense ® 61 receiving highly emetogenic 61 tumor xenograft models 61 colorectal cancer liver metastases 61 endocrine therapies 61 5 fluorouracil 61 castrate resistant 61 metastatic breast cancer 61 metastatic renal cell 61 HGS ETR1 61 doxorubicin HCl liposome injection 61 lymph node involvement 61 lymphoid malignancies 61 esophageal candidiasis 61 autoantibody positive 61 Fludara ® 61 evaluable 61 anthracyclines taxanes 61 oral clodronate 61 radiation sensitizer 61 non metastatic resectable 61 castrate resistant prostate cancer 61 recurrent colorectal cancer 61 androgen deprivation 61 Platinol ® cisplatin 61 urothelial carcinoma 61 systemic anaplastic large 61 imatinib therapy 61 PEGINTRON TM 61 advanced SCCHN 61 Sezary syndrome 61 cetuximab 61 metastatic colorectal carcinoma 61 chemoembolization 61 recurrent GBM 61 grade glioma 61 prostate carcinoma 61 pediatric Crohn disease 61 mycophenolate mofetil 61 opioid induced constipation OIC 61 Metastatic Colorectal Cancer 61 docetaxel 61 T#I mutation 61 cell lung cancer 61 HNSCC 61 Mitomycin C 61 imatinib mesylate 61 posaconazole 61 mildly symptomatic 61 gefitinib 61 cisplatin vinorelbine 61 smoldering multiple myeloma 61 bevacizumab 61 relapsed multiple myeloma 61 extracranial 61 Metastatic 61 lintuzumab SGN 61 myelodysplastic syndromes MDS 61 radical cystectomy 61 DMARDs 61 peritoneal carcinomatosis 61 EGFR mutation positive 61 mapatumumab 61 PEGylated interferon beta 1a 61 gefitinib Iressa 61 Taxotere R 61 mitomycin C 61 androgen independent 61 severe renal impairment 61 ischemic cardiomyopathy 61 squamous cell histology 61 CMV disease 61 untreated multiple myeloma 61 mTOR inhibitor 61 DMARD 61 BCG refractory carcinoma 61 EFAPROXYN 61 splenectomized 61 follicular thyroid cancer 61 interferon gamma 1b 61 Phase #b/#a clinical 61 amrubicin 61 preoperative radiotherapy 61 Nexavar sorafenib 61 refractory metastatic colorectal cancer 61 EGFR expressing mCRC 61 relapsed CLL 61 calcineurin inhibitors 61 Herceptin trastuzumab 61 standard chemotherapy regimen 61 hormone receptor positive 61 resistant ovarian cancer 61 severe neutropenia 61 lupus nephritis 61 CsA 61 keloid scarring 61 locoregional recurrence 61 5-fluorouracil/leucovorin 61 renal insufficiency 61 ZACTIMA 61 clinically localized prostate 61 daunorubicin 61 cell carcinoma RCC 61 biochemical recurrence 61 haematologic 61 HBeAg positive patients 61 Aflibercept 60 transurethral resection 60 tocilizumab 60 romiplostim 60 gemcitabine cisplatin 60 plus prednisone 60 HRPC 60 allogeneic bone marrow 60 aplastic anemia AA 60 Gemzar ® 60 follicular NHL 60 PEGylated Fab fragment 60 advanced adenomas 60 transitional cell carcinoma 60 low dose cytarabine 60 Relapsed Refractory 60 myelodysplastic syndromes 60 PegIntron 60 unresectable liver cancer 60 dacarbazine chemotherapy 60 alkylating agents 60 minimally symptomatic metastatic castrate 60 refractory CTCL 60 T1c 60 evaluating tivozanib 60 Vicinium TM 60 thalidomide Thalomid 60 prior chemotherapy regimens 60 neoadjuvant treatment 60 evaluating picoplatin 60 TNF antagonists 60 LHRH receptor positive 60 imatinib Gleevec ® 60 FIRMAGON 60 severe oral mucositis 60 NMIBC 60 OPAXIO 60 untreated metastatic melanoma 60 EGFR TKI 60 Acute Myeloid Leukemia AML 60 gemcitabine Gemzar 60 K ras mutations 60 TNF antagonist 60 IIIA NSCLC 60 spinal cord compression 60 PREZISTA r 60 PEGylated anti 60 dose cytarabine 60 PD LID 60 biologic DMARD 60 Free Survival PFS 60 radiofrequency ablation RFA 60 anaplastic astrocytoma AA 60 ErbB2 positive 60 histone deacetylase HDAC inhibitor 60 sorafenib tablets 60 BRIM2 60 INCB# [003] 60 fluorouracil leucovorin 60 unstable angina UA 60 luteinizing hormone releasing 60 oral vancomycin 60 voriconazole 60 ASCT 60 intravesical infusion therapy 60 sunitinib malate 60 alvespimycin 60 huN# DM1 60 radiochemotherapy 60 activating EGFR mutations 60 lenalidomide dexamethasone 60 beclomethasone dipropionate 60 5 FU leucovorin 60 monotherapy 60 peripheral sensory neuropathy 60 hepatorenal syndrome 60 adecatumumab 60 elacytarabine 60 neoplasm 60 8mg/kg 60 tumor lysis syndrome 60 relapsed ovarian cancer 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 Ph + ALL 60 relapsed leukemia 60 HBeAg positive 60 peritoneal cancer 60 carboplatin 60 hematologic disorders 60 subependymal giant cell 60 adalimumab 60 carcinoid tumors 60 ara C 60 TELINTRA 60 AVASTIN 60 EBRT 60 xanthine oxidase inhibitor 60 liver resection 60 ixabepilone 60 SCIg 60 carcinoma HCC 60 acute GvHD 60 decompensated liver disease 60 Erlotinib 60 ALND 60 superficial basal cell carcinoma 60 hepatocellular carcinoma 60 mutated KRAS gene 60 MYLOTARG 60 deletion 5q 60 Troxatyl 60 relapsing remitting 60 metastatic carcinoid 60 decitabine 60 phase IIb clinical 60 cell chronic lymphocytic 60 Gliadel Wafer 60 R lenalidomide 60 free survival PFS 60 lymph node dissection 60 transplantation HCT 60 investigational immunotherapy 60 leukemia APL 60 Certolizumab pegol 60 MabCampath 60 hereditary deficiency 60 CIMZIA TM 60 TYKERB 60 purpura ITP 60 evaluable patients 60 Fibrillex TM 60 XIENCE V PROMUS Stent 60 percutaneous transluminal coronary angioplasty 60 underwent surgical resection 60 Vectibix 60 Cytoxan 60 eribulin 60 refractory 60 ACR# responses 60 chronic lymphocytic leukemia CLL 59 palliation 59 Stage IIIA 59 R sorafenib tablets 59 chemotherapy regimens 59 intestinal metaplasia 59 glioblastoma multiforme GBM 59 endarterectomy 59 Vandetanib 59 telaprevir dosed 59 ALA PDT 59 mg q#h 59 occlusive disease 59 Squamous 59 paroxysmal AF 59 Proxinium TM 59 ZOLINZA 59 glycoprotein IIb IIIa inhibitors 59 debulking surgery 59 interferon alfa 59 symptomatic BPH 59 corticosteroid therapy 59 indolent NHL 59 squamous cell carcinoma SCC 59 SHPT 59 allogeneic hematopoietic stem cell 59 Zavesca R 59 chemoresistant 59 stable angina 59 bevacizumab Avastin R 59 TO AVOID PREGNANCY WHILE 59 aHUS 59 non valvular atrial 59 prostate cancer mCRPC 59 Cloretazine 59 TKI therapy 59 Hodgkin lymphoma NHL 59 neutropenia dehydration dyspnea 59 #mg BID [001] 59 squamous non 59 alkylating agent 59 FOLFOX regimen 59 FOLFOX chemotherapy 59 melphalan 59 FASLODEX 59 RECIST Response Evaluation Criteria 59 GP IIb IIIa inhibitors 59 sorafenib Nexavar ® 59 ARIXTRA 59 mCRPC 59 contralateral breast 59 HBeAg negative patients 59 Paraplatin ® carboplatin 59 methotrexate therapy 59 chemotherapy docetaxel 59 candesartan cilexetil 59 IgG1 monoclonal antibody 59 familial amyloidotic polyneuropathy FAP 59 BARACLUDE ® 59 cell carcinoma 59 invasive bladder 59 papillary 59 diagnosed multiple myeloma 59 primary hypercholesterolemia 59 IRESSA 59 CAELYX 59 EGFR HER2 59 Unresectable 59 previously untreated follicular 59 capecitabine 59 colorectal carcinoma 59 bronchogenic carcinoma 59 grade gliomas 59 vinca alkaloids 59 HSCT 59 atypical Hemolytic Uremic Syndrome 59 relapsed GBM 59 TNF Tumor Necrosis Factor 59 hematologic toxicity 59 stable angina pectoris 59 partial remissions 59 carcinoids 59 LEUKINE 59 BR.# 59 refractory APL 59 cytotoxic therapy 59 esophagectomy 59 mitoxantrone 59 curative therapy 59 metastatic breast 59 pediatric malignancies 59 idiopathic pulmonary fibrosis IPF 59 intravesical instillation 59 CIMZIA TM certolizumab pegol 59 mitoxantrone chemotherapy 59 Flu Cy 59 pericardial effusion 59 myelofibrosis MF 59 venous thromboembolic events 59 gastric adenocarcinoma 59 cytoreductive nephrectomy 59 situ LCIS 59 demonstrated antitumor activity 59 ELACYT 59 NYHA Class III 59 cabazitaxel 59 PAOD 59 invasive aspergillosis 59 tyrosine kinase inhibitors TKIs 59 febrile neutropenia 59 temozolomide 59 primary humoral immunodeficiency 59 coronary revascularization 59 advanced epithelial ovarian 59 Alemtuzumab 59 sarcomatoid 59 dasatinib 59 breast carcinoma 59 pain palliation 59 refractory CLL 59 pegylated interferon alfa 2b 59 CR nPR 59 Sorafenib 59 HERCEPTIN 59 FluCAM arm 59 Toxicities 59 severe exacerbations 59 recurrent malignant glioma 59 Papillary 59 paclitaxel Taxol ® 59 mutated KRAS 59 Velcade bortezomib 59 metastatic CRPC 59 taxane resistant 59 cholangiocarcinoma 59 diagnosed glioblastoma multiforme 59 Telintra 59 sleeve lobectomy 59 alfa 2a 59 external beam radiotherapy 59 Onrigin 59 calcineurin inhibitor 59 receiving prophylactic anticoagulation 59 MAGE A3 ASCI 59 adverse cytogenetics 59 talactoferrin 59 TAXOTERE R 59 paclitaxel cisplatin 59 neuroendocrine tumors 59 pancreatic neuroendocrine tumors 59 metastases 59 satraplatin Phase 59 Glioblastoma Multiforme GBM 59 moderate renal impairment 59 Tamibarotene 59 goserelin 59 HCV genotype 59 nephrectomy 59 assessing T DM1 59 Hodgkin lymphoma HL 59 CML CP 59 Follicular Lymphoma 59 Uricase PEG 59 Relapsed Refractory Multiple Myeloma 59 biochemical relapse 59 RhuDex ® 59 thoracoscopic lobectomy 59 recurrent ovarian cancer 59 micrometastases 59 localized prostate cancer 59 TRAIL R1 59 surgically resectable 59 refractory metastatic 59 OncoVEX GM CSF 59 osteosarcoma Ewing sarcoma 59 bone metastasis 59 refractory acute promyelocytic 59 weekly subcutaneous injections 58 antitumor activity 58 efalizumab 58 dasatinib Sprycel 58 median PFS 58 metastatic kidney 58 varices 58 #mg/m# [001] 58 MALT lymphoma 58 Elitek 58 invasive candidiasis 58 radiation chemoradiation 58 advanced metastatic prostate 58 Epratuzumab 58 oral ridaforolimus 58 paclitaxel poliglumex 58 AA Amyloidosis 58 relapsed Acute Myeloid 58 mycosis fungoides 58 chemotherapeutic regimens 58 novel VDA molecule 58 Voreloxin 58 advanced medullary thyroid 58 hormone LHRH agonist 58 iniparib 58 tyrosine kinase inhibitors 58 Peg IFN 58 Cell Lung Cancer 58 nilotinib 58 advanced carcinoid 58 Vitaxin 58 huC# DM4 58 NATRECOR R 58 nonsquamous histology 58 pertuzumab 58 Ceflatonin 58 histologic subtype 58 advanced pancreatic neuroendocrine 58 Allovectin 7 58 PNP inhibitor 58 nucleoside analog 58 peginterferon alfa 58 antiarrhythmic drug 58 zalutumumab 58 modified glutathione analog 58 MACCE 58 parathyroid carcinoma 58 Percutaneous Coronary Intervention 58 ThermoDox R 58 refractory indolent non 58 panitumumab Vectibix 58 Bevacizumab 58 GIST 58 metastatic colon cancer 58 cytogenetic response 58 endoscopic remission 58 surgical debulking 58 cell lymphoma ALCL 58 intravesical 58 chronic idiopathic thrombocytopenic purpura 58 hormone refractory metastatic prostate 58 herpetic keratitis 58 Daclizumab 58 extranodal 58 tiuxetan 58 Avastin bevacizumab 58 adalimumab Humira 58 alpha interferons 58 methotrexate monotherapy 58 vinca alkaloid 58 IL# PE#QQR 58 AGILECT R 58 GLIADEL R Wafer 58 EGFR mutations 58 Lambert Eaton Myasthenic 58 metastatic renal 58 occlusion PAO 58 skeletal metastases 58 FluCAM 58 EGFR mutation 58 bortezomib 58 GvHD 58 pegylated alpha interferon 58 partial nephrectomy 58 Clolar ® 58 pamidronate 58 rilonacept 58 Everolimus 58 hematologic malignancies 58 unfavorable cytogenetics 58 mg/m2 dose 58 dose dexamethasone 58 alemtuzumab treated 58 IV malignant melanoma 58 peginterferon alfa 2a Pegasys 58 HGS ETR2 58 DMARD therapy 58 COPEGUS 58 oblimersen 58 certolizumab 58 ipsilateral breast 58 prostate adenocarcinoma 58 Mitoxantrone 58 #D#C# 58 chronic thromboembolic pulmonary 58 nab paclitaxel 58 EGFR inhibitors 58 anaplastic astrocytoma 58 TEMODAL 58 lobectomy 58 trans retinoic acid ATRA 58 autologous SCT 58 octreotide 58 pegfilgrastim 58 axillary lymph node 58 pulmonary metastases 58 patients undergoing CABG 58 tanespimycin 58 paclitaxel Taxol R 58 ® lenalidomide 58 Chronic Lymphocytic Leukemia 58 tuberous sclerosis TS 58 Tiuxetan 58 flutamide 58 QuadraSphere 58 dopamine partial agonist 58 TNF inhibitor 58 gemcitabine Gemzar ® 58 VIDAZA 58 mcg albinterferon alfa 2b 58 clodronate 58 dosing cohort 58 XGEVA 58 cT3 prostate cancer 58 elevated LDH 58 resectable pancreatic cancer 58 Decitabine 58 neoplasias 58 portal vein thrombosis 58 6 mercaptopurine 58 abacavir lamivudine 58 paraganglioma 58 renal impairment 58 malignant neoplasm 58 oropharyngeal candidiasis OPC 58 rFVIIa 58 renal dysfunction 58 paroxysmal nocturnal hemoglobinuria PNH 58 bosutinib 58 trastuzumab 58 Glufosfamide 58 mg kg dose 58 anthracyclines 58 Glioblastoma Multiforme 58 everolimus eluting stents 58 refractory PTCL 58 HCV genotype 1 58 myelofibrosis 58 trastuzumab Herceptin R 58 Clevudine 58 generalized edema 58 catheter occlusion 58 Syndrome LEMS 58 non squamous histology 58 interstitial pneumonitis 58 BAY #-# 58 FOLFIRI alone 58 sunitinib Sutent ® 58 hepatitis C HCV 58 veno occlusive disease 58 Philadelphia Chromosome Positive 58 invasive fungal infections 58 operable breast cancer 58 tamibarotene 58 graft dysfunction 58 biliary strictures 58 Hsp# Inhibitor 58 acute myeloid 58 mg BID 58 primary immunodeficiency PI 58 macroalbuminuria 58 total thyroidectomy 58 pegylated interferon 58 BRCA deficient 58 lenalidomide 58 ELOXATIN 58 dependent kinase inhibitor 58 Cystectomy 58 acute peripheral arterial 58 TAXUS Express Stent 58 Hycamtin ® 58 fibrinolytic therapy 58 erlotinib 58 Interferon alfa 58 pulmonary artery banding 58 Copegus ribavirin 58 Gleevec resistant 58 relapsed acute myelogenous 58 Bortezomib 58 cutaneous melanoma 58 6R BH4 58 tumor resection 58 anthracycline therapy 58 MGd 58 saphenous vein graft 58 FUSILEV enhances 58 rituximab refractory 58 acute myelogenous leukemia AML 58 refractory ovarian cancer 58 squamous cell 58 asymptomatic metastatic 58 CCyR 58 mitomycin 58 Sandostatin LAR 58 novel histone deacetylase 58 chronic ITP 58 AA amyloidosis 58 lymphadenopathy 58 cyclophosphamide methotrexate 58 chronic immune thrombocytopenic 58 recurrent squamous cell carcinoma 58 adjuvant therapies 58 pyrexia mucositis sepsis febrile 58 progression TTP 58 rosuvastatin #mg 58 myeloproliferative diseases 58 Diffuse Large B 58 somatostatin analogues 58 Cimzia TM 58 pegylated interferon alpha 58 deep venous thromboses 58 malignant neoplasms 58 oral antidiabetic medication